30 studies found for:    MPDL3280A
Show Display Options
Rank Status Study
1 Not yet recruiting A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Patients With Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: MPDL3280A
2 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafenib (Zelboraf®) or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: MPDL3280A;   Drug: Vemurafenib (Zelboraf®);   Drug: cobimetinib
3 Recruiting A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: Interferon alfa-2b;   Drug: Ipilimumab;   Drug: MPDL3280A
4 Not yet recruiting MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A;   Radiation: Stereotactic Body Radiation Therapy
5 Recruiting A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Condition: Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: MPDL3280A
6 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: FOLFOX;   Drug: MPDL3280A;   Drug: bevacizumab [Avastin];   Drug: carboplatin;   Drug: nab-paclitaxel;   Drug: paclitaxel;   Drug: pemetrexed
7 Recruiting A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: MPDL3280A;   Drug: bevacizumab [Avastin];   Drug: sunitinib
8 Recruiting A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Chemotherapy;   Drug: MPDL3280A
9 Recruiting A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: INCB024360
10 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: erlotinib [Tarceva[;   Drug: erlotinib [Tarceva]
11 Recruiting A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition: Carcinoma, Transitional Cell , Bladder Cancer, Bladder Tumors, Urinary Bladder Neoplasms
Intervention: Drug: MPDL3280A
12 Not yet recruiting A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: MPDL3280A;   Drug: RO6895882
13 Recruiting A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: MPDL3280A;   Drug: RO7009789
14 Active, not recruiting A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR"
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
15 Recruiting A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Tumor
Interventions: Drug: MOXR0916;   Drug: MPDL3280A
16 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: Cobimetinib;   Drug: MPDL3280A
17 Recruiting A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Condition: Follicular Lymphoma, Lymphoma, B-Cell
Interventions: Drug: MPDL3280A;   Drug: Obinutuzumab
18 Recruiting A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors
Condition: Solid Cancers
Interventions: Drug: MPDL3280A;   Drug: RO5509554
19 Recruiting A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Drug: MPDL3280A;   Drug: Pemetrexed
20 Recruiting A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Intervention: Drug: MPDL3280A

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
Indicates status has not been verified in more than two years